Stoke TherapeuticsFRA:0GT -2.84%43 PB Ratio is 5.05 as of Jul. 08, 2026, which is 101% above its 10-year median of 2.51. GuruFocus rates FRA:0GT with a GF Score™ of 43/100 and a GF Value™ of €8.50 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,225 Biotechnology companies, Stoke Therapeutics ranks worse than 70.53% on this metric.
The historical rank and industry rank for Stoke Therapeutics's PB Ratio or its related term are showing as below:
FRA:0GT'
s PB Ratio Range Over the Past 10 Years
Min: 0.86 Med: 2.51 Max: 6.09
Current: 5.2
During the past 9 years, Stoke Therapeutics's highest PB Ratio was 6.09. The lowest was 0.86. And the median was 2.51.
FRA:0GT's PB Ratio is ranked worse than 70.53% of 1225
companies
in the Biotechnology industry
Industry Median: 2.92
vs FRA:0GT: 5.20
During the past 12 months, Stoke Therapeutics's average Book Value Per Share Growth Rate was -1.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 8.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -7.20% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Stoke Therapeutics was 19.40% per year. The lowest was -23.70% per year. And the median was -10.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Stoke Therapeutics PB Ratio Related Terms
Stoke Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Stoke Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Stoke Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stoke Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stoke Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Stoke Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Stoke Therapeutics (FRA:0GT) has a PB Ratio of 5.05 as of Jul. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Stoke Therapeutics and its competitors. This is 101% above median its historical median of 2.51. Over the past decade, Stoke Therapeutics' PB Ratio has ranged from 0.86 to 6.09. According to the industry distribution chart, Stoke Therapeutics ranks #864 out of 1225 companies in the Biotechnology industry, placing it in the top 70.5%.
Is Stoke Therapeutics' PB Ratio too high?
Stoke Therapeutics' current PB Ratio of 5.05 is 101% above median its 10-year median of 2.51. Over the past 10 years, this metric has ranged from a low of 0.86 to a high of 6.09. The Biotechnology industry median PB Ratio is 2.92. Stoke Therapeutics' value of 5.05 is 72.9% above this industry median. Based on the distribution chart, Stoke Therapeutics ranks #864 out of 1225 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Stoke Therapeutics has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stoke Therapeutics' PB Ratio compare to VRDN and ZLAB?
According to the Biotechnology industry distribution chart, Stoke Therapeutics ranks #864 out of 1225 companies for PB Ratio. This places Stoke Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.92. Stoke Therapeutics' value of 5.05 is 72.9% above this benchmark. Historically, Stoke Therapeutics' own PB Ratio has ranged from 0.86 to 6.09 over the past decade. While the company's 10-year median is 2.51 vs. the industry median of 2.92, Stoke Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.92, based on 1,225 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stoke Therapeutics's current PB Ratio of 5.05 is 72.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Stoke Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stoke Therapeutics's current PB Ratio is 5.05, which is 101% above median its own 10-year median of 2.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stoke Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Stoke Therapeutics (FRA:0GT) is currently considered Significantly Overvalued. The stock's GF Value™ is €8.50, compared to a current price of €27.72 — trading 226.1% above its estimated fair value. The current PB Ratio is 5.05, which is 101% above median its 10-year median of 2.51 and 72.9% above the Biotechnology industry median of 2.92. Stoke Therapeutics' overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Stoke Therapeutics (FRA:0GT), the current PB Ratio is 5.05 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stoke Therapeutics (FRA:0GT) Overvalued in 2026?
Based on GuruFocus' analysis, Stoke Therapeutics stock appears to be overvalued.
The current stock price of €27.72 is trading 226.1% above its estimated GF Value™ of €8.50.
GuruFocus considers Stoke Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:0GT:
PB Ratio: 5.05 (101% above median its 10-year median of 2.51)
GF Value™: €8.50 vs. price of €27.72 (226.1% above fair value)
Industry Position: 72.9% above the Biotechnology median (#864 of 1225)
No single metric tells the full story. See the FRA:0GT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
43GF Score
Get the complete analysis for FRA:0GT
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0GT has been successfully added to your 
